Blueprint Medicines Co. (NASDAQ:BPMC) Stock Holdings Lifted by Prosight Management LP

Prosight Management LP raised its stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 42.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 67,000 shares of the biotechnology company's stock after acquiring an additional 19,900 shares during the period. Blueprint Medicines makes up 1.6% of Prosight Management LP's portfolio, making the stock its 20th biggest position. Prosight Management LP owned approximately 0.11% of Blueprint Medicines worth $5,844,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in Blueprint Medicines by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 6,774,884 shares of the biotechnology company's stock valued at $590,905,000 after acquiring an additional 91,450 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Blueprint Medicines by 5.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,679,089 shares of the biotechnology company's stock valued at $495,331,000 after purchasing an additional 291,822 shares in the last quarter. Wellington Management Group LLP increased its stake in Blueprint Medicines by 8.0% in the 4th quarter. Wellington Management Group LLP now owns 4,281,364 shares of the biotechnology company's stock worth $373,421,000 after acquiring an additional 316,754 shares during the last quarter. William Blair Investment Management LLC grew its stake in shares of Blueprint Medicines by 16.1% in the 4th quarter. William Blair Investment Management LLC now owns 1,944,695 shares of the biotechnology company's stock worth $169,616,000 after buying an additional 269,896 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in Blueprint Medicines by 0.7% during the 4th quarter. Geode Capital Management LLC now owns 1,490,101 shares of the biotechnology company's stock valued at $129,996,000 after buying an additional 9,914 shares during the period.

Blueprint Medicines Trading Up 0.5%

Shares of BPMC stock traded up $0.53 during trading hours on Tuesday, hitting $101.75. 128,951 shares of the company were exchanged, compared to its average volume of 1,003,129. The firm has a fifty day moving average of $89.87 and a 200 day moving average of $94.47. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. Blueprint Medicines Co. has a 1 year low of $73.04 and a 1 year high of $121.90. The firm has a market cap of $6.57 billion, a PE ratio of -94.13 and a beta of 0.83.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.32). The company had revenue of $149.41 million during the quarter, compared to analyst estimates of $158.31 million. Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. The firm's revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter last year, the business earned $1.40 EPS. Analysts expect that Blueprint Medicines Co. will post -1.28 earnings per share for the current year.

Insiders Place Their Bets

In other Blueprint Medicines news, insider Ariel Hurley sold 3,203 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $92.62, for a total transaction of $296,661.86. Following the transaction, the insider now owns 18,270 shares in the company, valued at $1,692,167.40. The trade was a 14.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Christina Rossi sold 2,274 shares of the company's stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $95.02, for a total value of $216,075.48. Following the completion of the sale, the chief operating officer now directly owns 69,266 shares of the company's stock, valued at $6,581,655.32. The trade was a 3.18% decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,503 shares of company stock worth $1,027,931 over the last three months. 4.21% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have commented on BPMC. HC Wainwright reiterated a "buy" rating and issued a $135.00 target price on shares of Blueprint Medicines in a report on Friday, May 2nd. Wolfe Research began coverage on Blueprint Medicines in a research report on Tuesday, March 18th. They issued an "outperform" rating on the stock. JPMorgan Chase & Co. raised their price objective on Blueprint Medicines from $126.00 to $129.00 and gave the company an "overweight" rating in a report on Tuesday, February 4th. Needham & Company LLC decreased their target price on shares of Blueprint Medicines from $133.00 to $130.00 and set a "buy" rating on the stock in a research note on Monday, April 28th. Finally, Morgan Stanley initiated coverage on Blueprint Medicines in a research report on Thursday, March 20th. They issued an "equal weight" rating and a $100.00 price target for the company. Five equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Blueprint Medicines presently has an average rating of "Moderate Buy" and a consensus price target of $126.56.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.